Page 1 | Search Results | Diabetes | American Diabetes Association

1-16 of 16

Sort by

Sort Order Select

Journal Articles

When Does Metabolic Memory Start? Insights From the Association of Medical Diabetologists Annals Initiative on Stringent HbA_1c Targets

Giuseppina T. Russo, Antonio Nicolucci, Giuseppe Lucisano, Maria Chiara Rossi, Antonio Ceriello, Francesco Prattichizzo, Valeria Manicardi, Alberto Rocca, Paolo Di Bartolo, Salvatore De Cosmo, Graziano Di Cianni, Riccardo Candido

Diabetes 2024;74(1):75–81

https://doi.org/10.2337/db24-0166

Published: 17 October 2024

View article titled, When Does Metabolic Memory Start? Insights From the Association of Medical Diabetologists Annals Initiative on Stringent HbA<sub>1c</sub> Targets

Meeting Abstracts

1804-PUB: Switching from Glucagon-Like Peptide-1 Receptor Agonists Therapy to Second Generation Basal Insulins—Comparative Effectiveness Analysis of Glargine 300 U/mL vs. Degludec 100 U/mL—The RESTORE-G Real-World Study

RICCARDO CANDIDO, ANTONIO NICOLUCCI, MONICA LAROSA, MARIA CHIARA ROSSI, RAFFAELE NAPOLI, RESTORE-G STUDY GROUP

Diabetes 2023;72(Supplement_1):1804-PUB

https://doi.org/10.2337/db23-1804-PUB

Published: 23 June 2023

View article titled, 1804-PUB: Switching from Glucagon-Like Peptide-1 Receptor Agonists Therapy to Second Generation Basal Insulins—Comparative Effectiveness Analysis of Glargine 300 U/mL vs. Degludec 100 U/mL—The RESTORE-G Real-World Study

Meeting Abstracts

84-LB: Intensification of Glucagon-Like Peptide-1 Receptor Agonists Therapy with Glargine 300 U/mL or IDegLira—The RESTORE-G Real-World Study

RICCARDO CANDIDO, ANTONIO NICOLUCCI, MARIA CHIARA ROSSI, MONICA LAROSA, RAFFAELE NAPOLI, RESTORE-G STUDY GROUP

Diabetes 2023;72(Supplement_1):84-LB

https://doi.org/10.2337/db23-84-LB

Published: 20 June 2023

View article titled, 84-LB: Intensification of Glucagon-Like Peptide-1 Receptor Agonists Therapy with Glargine 300 U/mL or IDegLira—The RESTORE-G Real-World Study

Meeting Abstracts

779-P: Intensification of Glucagon-Like Peptide-1 Receptor Agonists Therapy with First and Second Generation Basal Insulins—The RESTORE-G Real-World Study

RAFFAELE NAPOLI, MONICA LAROSA, ANTONIO NICOLUCCI, MARIA CHIARA ROSSI, RICCARDO CANDIDO, RESTORE-G STUDY GROUP

Diabetes 2023;72(Supplement_1):779-P

https://doi.org/10.2337/db23-779-P

Published: 20 June 2023

View article titled, 779-P: Intensification of Glucagon-Like Peptide-1 Receptor Agonists Therapy with First and Second Generation Basal Insulins—The RESTORE-G Real-World Study

Meeting Abstracts

87-LB: Treatment Intensification after Glucagon-Like Peptide-1 Receptor Agonists Therapy in Type 2 Diabetes—The RESTORE-G Real-World Study

RICCARDO CANDIDO, ANTONIO NICOLUCCI, MONICA LAROSA, MARIA CHIARA ROSSI, RAFFAELE NAPOLI, RESTORE-G STUDY GROUP

Diabetes 2022;71(Supplement_1):87-LB

https://doi.org/10.2337/db22-87-LB

Published: 01 June 2022

View article titled, 87-LB: Treatment Intensification after Glucagon-Like Peptide-1 Receptor Agonists Therapy in Type 2 Diabetes—The RESTORE-G Real-World Study

Meeting Abstracts

1167-P: Burden of Cardiorenal Complications (CRCs) in T2D: Take Care of Me Programme

KAMLESH KHUNTI, PETER FENICI, SUSANA GONCALVES, HIDDO L. HEERSPINK, SHASHANK JOSHI, MIKHAIL N. KOSIBOROD, CAROLYN S. LAM, ANTONIO NICOLUCCI, LARISA RAMIREZ, ALEJANDRA I. SILVA, II, FILIP SURMONT, HARDIK VASNAWALA, ESTEFANIA VAZQUEZ-MENDEZ

Diabetes 2022;71(Supplement_1):1167-P

https://doi.org/10.2337/db22-1167-P

Published: 01 June 2022

View article titled, 1167-P: Burden of Cardiorenal Complications (CRCs) in T2D: Take Care of Me Programme

Meeting Abstracts

109-LB: Comparative Effectiveness of Insulin Glargine 300 U/mL (Gla-300) and Insulin Degludec 100 U/mL (iDeg-100) in Insulin-Naïve Type 2 Diabetes Adults: RESTORE-2 Real-World Study

GIAN PAOLO FADINI, RAFFAELLA BUZZETTI, ANTONIO NICOLUCCI, MARIA CHIARA ROSSI, MONICA LAROSA, DOMENICO CUCINOTTA, ON BEHALF OF RESTORE-2 STUDY GROUP

Diabetes 2021;70(Supplement_1):109-LB

https://doi.org/10.2337/db21-109-LB

Published: 01 June 2021

View article titled, 109-LB: Comparative Effectiveness of Insulin Glargine 300 U/mL (Gla-300) and Insulin Degludec 100 U/mL (iDeg-100) in Insulin-Naïve Type 2 Diabetes Adults: RESTORE-2 Real-World Study

Meeting Abstracts

110-LB: Efficacy, Safety, and Appropriateness of iGlarLixi, a Fixed-Ratio Combination (FRC) in Type 2 Diabetes (T2D) in Real-World Settings: Results from the ENSURE Study

RICCARDO CANDIDO, MONICA MODUGNO, ENRICO GABELLIERI, ANTONIO NICOLUCCI, MARIA CHIARA ROSSI, MONICA LAROSA, ON BEHALF OF ENSURE STUDY GROUP

Diabetes 2021;70(Supplement_1):110-LB

https://doi.org/10.2337/db21-110-LB

Published: 01 June 2021

View article titled, 110-LB: Efficacy, Safety, and Appropriateness of iGlarLixi, a Fixed-Ratio Combination (FRC) in Type 2 Diabetes (T2D) in Real-World Settings: Results from the ENSURE Study

Meeting Abstracts

40-OR: Quality of Life in People with Type 2 Diabetes following Initiation of Second-Line Therapy: DISCOVER

ANTONIO NICOLUCCI, HUNGTA CHEN, ANDREW COOPER, MARILIA B. GOMES, LINONG JI, KAMLESH KHUNTI, MIKHAIL N. KOSIBOROD, PAUL LEIGH, LARISA RAMIREZ, MARINA V. SHESTAKOVA, IICHIRO SHIMOMURA, AFRAH SIDDIQUI, FENGMING TANG, JITEN VORA, HIROTAKA WATADA, SUZANNE V. ARNOLD

Diabetes 2020;69(Supplement_1):40-OR

https://doi.org/10.2337/db20-40-OR

Published: 01 June 2020

View article titled, 40-OR: Quality of Life in People with Type 2 Diabetes following Initiation of Second-Line Therapy: DISCOVER

Meeting Abstracts

1590-P: Effects of Second-Line Metformin Combination Therapies on Weight, HbA1c, and Risk of Hypoglycemia over 3 Years: The DISCOVER Study

KAMLESH KHUNTI, BERNARD CHARBONNEL, ANDREW COOPER, MARILIA B. GOMES, LINONG JI, PAUL LEIGH, ANTONIO NICOLUCCI, WOLFGANG RATHMANN, MARINA V. SHESTAKOVA, AFRAH SIDDIQUI, FENGMING TANG, HIROTAKA WATADA, HUNGTA CHEN

Diabetes 2020;69(Supplement_1):1590-P

https://doi.org/10.2337/db20-1590-P

Published: 01 June 2020

View article titled, 1590-P: Effects of Second-Line Metformin Combination Therapies on Weight, HbA1c, and Risk of Hypoglycemia over 3 Years: The DISCOVER Study

Meeting Abstracts

1448-P: Potential Overtreatment of Older Patients with T2D: The Global DISCOVER Study

Diabetes 2019;68(Supplement_1):1448-P

https://doi.org/10.2337/db19-1448-P

Published: 01 June 2019

View article titled, 1448-P: Potential Overtreatment of Older Patients with T2D: The Global DISCOVER Study

Meeting Abstracts

420-P: Micro- and Macrovascular Events in Patients with T2D—Results from the Global DISCOVER Study

SUZANNE V. ARNOLD, HUNGTA CHEN, JAVIER CID-RUZAFA, PETER FENICI, MARILIA B. GOMES, KAMLESH KHUNTI, GABRIELA LUPORINI SARAIVA, JESUS MEDINA, ANTONIO NICOLUCCI, STUART POCOCK, SHAUKAT M. SADIKOT, MARINA V. SHESTAKOVA, IICHIRO SHIMOMURA, FILIP SURMONT, FENGMING TANG, JITEN VORA, HIROTAKA WATADA, MIKHAIL N. KOSIBOROD

Diabetes 2019;68(Supplement_1):420-P

https://doi.org/10.2337/db19-420-P

Published: 01 June 2019

View article titled, 420-P: Micro- and Macrovascular Events in Patients with T2D—Results from the Global DISCOVER Study

Meeting Abstracts

1225-P: The Association between Long-Term Glucose Variability (GV), Cardiovascular (CV) Death, and Heart Failure (HF) Outcomes in the EMPA-REG OUTCOME Trial

ANTONIO CERIELLO, ANNE PERNILLE OFSTAD, ISABELLA ZWIENER, STEFAN KASPERS, JYOTHIS GEORGE, ANTONIO NICOLUCCI

Diabetes 2019;68(Supplement_1):1225-P

https://doi.org/10.2337/db19-1225-P

Published: 01 June 2019

View article titled, 1225-P: The Association between Long-Term Glucose Variability (GV), Cardiovascular (CV) Death, and Heart Failure (HF) Outcomes in the EMPA-REG OUTCOME Trial

Meeting Abstracts

1628-P: Changes in HbA_1c and Treatment in the Second Year following Initiation of Second-Line Therapy in People with T2D—The Global DISCOVER Study

BERNARD CHARBONNEL, HUNGTA CHEN, JAVIER CID-RUZAFA, PETER FENICI, MARILIA B. GOMES, GABRIELA LUPORINI SARAIVA, JESUS MEDINA, ANTONIO NICOLUCCI, STUART POCOCK, MARINA V. SHESTAKOVA, IICHIRO SHIMOMURA, SHAUKAT M. SADIKOT, FILIP SURMONT, FENGMING TANG, JITEN VORA, HIROTAKA WATADA, KAMLESH KHUNTI

Diabetes 2019;68(Supplement_1):1628-P

https://doi.org/10.2337/db19-1628-P

Published: 01 June 2019

View article titled, 1628-P: Changes in HbA<sub>1c</sub> and Treatment in the Second Year following Initiation of Second-Line Therapy in People with T2D—The Global DISCOVER Study

Meeting Abstracts

1279-P: Socioeconomic Factors Associated with Poor Glycemic Control in People with Type 2 Diabetes: The DISCOVER Study

MARILIA B. GOMES, FENGMING TANG, HUNGTA CHEN, JAVIER CID-RUZAFA, PETER FENICI, KAMLESH KHUNTI, STUART POCOCK, WOLFGANG RATHMANN, MARINA V. SHESTAKOVA, FILIP SURMONT, HIROTAKA WATADA, JESUS MEDINA, SHAUKAT M. SADIKOT, IICHIRO SHIMOMURA, GABRIELA LUPORINI SARAIVA, ANTONIO NICOLUCCI

Diabetes 2019;68(Supplement_1):1279-P

https://doi.org/10.2337/db19-1279-P

Published: 01 June 2019

View article titled, 1279-P: Socioeconomic Factors Associated with Poor Glycemic Control in People with Type 2 Diabetes: The DISCOVER Study

Meeting Abstracts

Development and Validation of a Pattern-Recognition Engine for Visualization of Glycemic Patterns in Individuals Performing Low-Frequency SMBG

GIACOMO VESPASIANI, ANTONIO NICOLUCCI, MILENA SALEH, JOCHEN SIEBER, GIUSEPPE PROSPERINI, CONCETTA SURACI, MARIANNA GALETTA, GIORGIO GRASSI

Diabetes 2018;67(Supplement_1):916-P

https://doi.org/10.2337/db18-916-P

Published: 01 July 2018

View article titled, Development and Validation of a Pattern-Recognition Engine for Visualization of Glycemic Patterns in Individuals Performing Low-Frequency SMBG

NARROW

When Does Metabolic Memory Start? Insights From the Association of Medical Diabetologists Annals Initiative on Stringent HbA_1c Targets

1804-PUB: Switching from Glucagon-Like Peptide-1 Receptor Agonists Therapy to Second Generation Basal Insulins—Comparative Effectiveness Analysis of Glargine 300 U/mL vs. Degludec 100 U/mL—The RESTORE-G Real-World Study

84-LB: Intensification of Glucagon-Like Peptide-1 Receptor Agonists Therapy with Glargine 300 U/mL or IDegLira—The RESTORE-G Real-World Study

779-P: Intensification of Glucagon-Like Peptide-1 Receptor Agonists Therapy with First and Second Generation Basal Insulins—The RESTORE-G Real-World Study

87-LB: Treatment Intensification after Glucagon-Like Peptide-1 Receptor Agonists Therapy in Type 2 Diabetes—The RESTORE-G Real-World Study

1167-P: Burden of Cardiorenal Complications (CRCs) in T2D: Take Care of Me Programme

109-LB: Comparative Effectiveness of Insulin Glargine 300 U/mL (Gla-300) and Insulin Degludec 100 U/mL (iDeg-100) in Insulin-Naïve Type 2 Diabetes Adults: RESTORE-2 Real-World Study

110-LB: Efficacy, Safety, and Appropriateness of iGlarLixi, a Fixed-Ratio Combination (FRC) in Type 2 Diabetes (T2D) in Real-World Settings: Results from the ENSURE Study

40-OR: Quality of Life in People with Type 2 Diabetes following Initiation of Second-Line Therapy: DISCOVER

1590-P: Effects of Second-Line Metformin Combination Therapies on Weight, HbA1c, and Risk of Hypoglycemia over 3 Years: The DISCOVER Study

1448-P: Potential Overtreatment of Older Patients with T2D: The Global DISCOVER Study

420-P: Micro- and Macrovascular Events in Patients with T2D—Results from the Global DISCOVER Study

1225-P: The Association between Long-Term Glucose Variability (GV), Cardiovascular (CV) Death, and Heart Failure (HF) Outcomes in the EMPA-REG OUTCOME Trial

1628-P: Changes in HbA_1c and Treatment in the Second Year following Initiation of Second-Line Therapy in People with T2D—The Global DISCOVER Study

1279-P: Socioeconomic Factors Associated with Poor Glycemic Control in People with Type 2 Diabetes: The DISCOVER Study

Development and Validation of a Pattern-Recognition Engine for Visualization of Glycemic Patterns in Individuals Performing Low-Frequency SMBG

Email alerts

Journals

Books

Clinical Compendia

News

Podcasts

Other

About

Resources

Email alerts

Journals

Books

Clinical Compendia

News

Podcasts

Other

About

Resources

This Feature Is Available To Subscribers Only